Sangamo BioSciences, Inc. - Product Pipeline Review - 2014

Published: Feb, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Sangamo BioSciences, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Sangamo BioSciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Sangamo BioSciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sangamo BioSciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Sangamo BioSciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sangamo BioSciences, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Sangamo BioSciences, Inc.'s pipeline products

Reasons to buy

- Evaluate Sangamo BioSciences, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sangamo BioSciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sangamo BioSciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sangamo BioSciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sangamo BioSciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sangamo BioSciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Sangamo BioSciences, Inc. Snapshot 5
Sangamo BioSciences, Inc. Overview 5
Key Information 5
Key Facts 5
Sangamo BioSciences, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Sangamo BioSciences, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Sangamo BioSciences, Inc. - Pipeline Products Glance 11
Sangamo BioSciences, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Sangamo BioSciences, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Sangamo BioSciences, Inc. - Drug Profiles 15
CERE-110 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
SB-728-T 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
SB-313 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
SB-728 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
SB-XXX Targeting CCR5 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SB-XXX Targetting CXCR4 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ZFN-Corrected iPSCs 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ZFP Nucleases for Hemophilia 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ZFP Transcription Factors for Hemoglobinopathies 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ZFP Transcription Factors For Huntington's Disease 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ZFP Transcription Factors for Lysosomal Storage Diseases 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ZFP Transcription Factors for Neuropathic Pain 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ZFP Transcription Factors for Parkinsons Disease 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ZFP Transcription Factors for X-Linked SCID 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Sangamo BioSciences, Inc. - Pipeline Analysis 32
Sangamo BioSciences, Inc. - Pipeline Products by Target 32
Sangamo BioSciences, Inc. - Pipeline Products by Route of Administration 34
Sangamo BioSciences, Inc. - Pipeline Products by Molecule Type 35
Sangamo BioSciences, Inc. - Pipeline Products by Mechanism of Action 36
Sangamo BioSciences, Inc. - Recent Pipeline Updates 38
Sangamo BioSciences, Inc. - Dormant Projects 46
Sangamo BioSciences, Inc. - Discontinued Pipeline Products 47
Discontinued Pipeline Product Profiles 47
SB-509 47
Sangamo BioSciences, Inc. - Company Statement 48
Sangamo BioSciences, Inc. - Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Sangamo BioSciences, Inc., Key Information 5
Sangamo BioSciences, Inc., Key Facts 5
Sangamo BioSciences, Inc. - Pipeline by Indication, 2014 8
Sangamo BioSciences, Inc. - Pipeline by Stage of Development, 2014 9
Sangamo BioSciences, Inc. - Monotherapy Products in Pipeline, 2014 10
Sangamo BioSciences, Inc. - Phase II, 2014 11
Sangamo BioSciences, Inc. - Phase I, 2014 12
Sangamo BioSciences, Inc. - Preclinical, 2014 13
Sangamo BioSciences, Inc. - Discovery, 2014 14
Sangamo BioSciences, Inc. - Pipeline by Target, 2014 33
Sangamo BioSciences, Inc. - Pipeline by Route of Administration, 2014 34
Sangamo BioSciences, Inc. - Pipeline by Molecule Type, 2014 35
Sangamo BioSciences, Inc. - Pipeline Products by Mechanism of Action, 2014 37
Sangamo BioSciences, Inc. - Recent Pipeline Updates, 2014 38
Sangamo BioSciences, Inc. - Dormant Developmental Projects,2014 46
Sangamo BioSciences, Inc. - Discontinued Pipeline Products, 2014 47
Sangamo BioSciences, Inc., Subsidiaries 50